Visceral Pain - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Visceral Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Visceral Pain - Pipeline Review, H2 2014', provides an overview of the Visceral Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Visceral Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Visceral Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Visceral Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Visceral Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Visceral Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Visceral Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Visceral Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Visceral Pain Overview 6
Therapeutics Development 7
Pipeline Products for Visceral Pain - Overview 7
Pipeline Products for Visceral Pain - Comparative Analysis 8
Visceral Pain - Therapeutics under Development by Companies 9
Visceral Pain - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Visceral Pain - Products under Development by Companies 12
Visceral Pain - Companies Involved in Therapeutics Development 13
Nektar Therapeutics 13
Astellas Pharma Inc. 14
Neurim Pharmaceuticals Ltd 15
Grunenthal GmbH 16
Trevena, Inc. 17
Hydra Biosciences, Inc. 18
GIcare Pharma Inc 19
Istituto Italiano di Tecnologia 20
Visceral Pain - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 25
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 30
GIC-1001 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
piromelatine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HC-030031 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Agonize Kappa Opioid Receptor for CNS Disorder - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NeuP-12 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Agonize Delta Opioid Receptor for CNS Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NKTR-195 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ASP-7663 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
URB-937 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RO-656570 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Visceral Pain - Recent Pipeline Updates 43
Visceral Pain - Dormant Projects 44
Visceral Pain - Discontinued Products 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Visceral Pain, H2 2014 7
Number of Products under Development for Visceral Pain - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Visceral Pain - Pipeline by Nektar Therapeutics, H2 2014 13
Visceral Pain - Pipeline by Astellas Pharma Inc., H2 2014 14
Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2014 15
Visceral Pain - Pipeline by Grunenthal GmbH, H2 2014 16
Visceral Pain - Pipeline by Trevena, Inc., H2 2014 17
Visceral Pain - Pipeline by Hydra Biosciences, Inc., H2 2014 18
Visceral Pain - Pipeline by GIcare Pharma Inc, H2 2014 19
Visceral Pain - Pipeline by Istituto Italiano di Tecnologia, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 29
Visceral Pain Therapeutics - Recent Pipeline Updates, H2 2014 43
Visceral Pain - Dormant Projects, H2 2014 44
Visceral Pain - Discontinued Products, H2 2014 45